JPRN-UMIN000026023已完成1 期
A phase I/II study of a WT1-W10 immunotherapy against high-risk MDS and MDS overt AML. - A phase I/II study of a WT1-W10 immunotherapy against high-risk MDS and MDS overt AML.
Department of Hematology and respiratory Medicine, School of Medicine, Kochi University0 个研究点目标入组 60 人开始时间: 2017年2月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)patients with infectious diseases including active Tuberculosis which are poorly controlled. 2)patients with serious comorbidities (generally those with grade 3 or higher by the NCI-CTC criteria ver 3.0) 3)pregnant women, Breast feeding mothers 4)patients with severe mental problems. 5)patients who have already been recruited in other clinical trials. 6)Patients who have dropped out after starting this clinical trials.
研究者
相似试验
已完成
不适用
Phase I clinical trial of immunotherapy with WT1 peptide vaccine for hematological malignancies after stem cell transplantatioAcute myeloid or lymphoid leukemia malignant lymphoma multiple myelomaJPRN-UMIN000004753Osaka University6
已完成
不适用
Phase II clinical trial of immunotherapy with WT1 peptide vaccination for pediatric hematological malignancies after allogeneic stem cell transplantation.Acute lymphoid or myeloid leukemia, acute unclassified leukemia, malignant lymphomaJPRN-UMIN000005319Osaka University22
已完成
1 期
A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.Osteosarcoma Soft tissue sarcoma neuroblastoma Pediatric bone, soft tissue sarcoma at high risk of recurrence.JPRN-UMIN000005312Osaka Universty22
已完成
1 期
Phase I clinical study of a WT1-W10 peptide immunotherapy combined with standard treatment against diffuse midline glioma (WT1-TR-DMG).glioblastoma multiformeJPRN-UMIN000025452Cancer Vaccination Therapy Research Network Central Office, Department of Immunology, Kochi Medical School10
已完成
不适用
exploratory trial of a WT1-W10 immunotherapy against pancreatic cancer in combination with the standard S1 chemotherapy.pancreatic cancerJPRN-UMIN000026049Anti-tumor Immunotherapy Research Network, Department of Immunology, Shool Of Medicine, Kochi Univesity6